|
|
|
Our Current Projects:
Currently we are associated with Multi National Company for its project (Phase III) in the field of Nephrology, Gynaecology and with another MNC for its post market surveillance in oncology specialty.
This shows clinical research/pharma industry's faith upon us for precise and reliable data.
Ongoing Trials:
1. An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEXT 10.8 mg Given Every 12 Weeks with ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women with Oestrogen Receptor Positive Advanced Breast Cancer.
2. A multicenter, double blind, randomized, fully replicate, crossover, comparative pharmacokinetic and safety study in female patients to show essential similarity of a novel formulation of intravenous Actavis Docetaxel (Docetaxel 20 mg/ml ) concentrate for solution for infusion to provide 100mg/m˛ Docetaxel and commercially available TaxotereŽ (Docetaxel 40 mg/mL), concentrate for solution for infusion to provide 100 mg/m˛ Docetaxel.
3. A phase II study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer patient receiving Treatment with Gemcitabine.
4. Safety and Efficacy of Recombinant Human Granulocyte-colony Stimulating Factor-rhGCSF (ReliGrastTM or NeupogenŽ) in Patients with Chemotherapy Induced Neutropenia (Protocol No : GMX-GCSF-CT001)
5. A Open-Label Single-Arm observational Study of Pemetrexed in Combination with Cisplatin in Patients with Advanced stage IIB/IV Non-Small Cell Lung Cancer Cancer to assess the PFS. (Progression Free Survival) in Indian context.
An Observational Study to evaluate the safety and efficacy of Erbitux in combination with platinumum based chemotherapy, in the first - line therapy of Recurrent / Metastatic Squamous Cell Carcinoma of Head & Neck (SCCHN)
Study No. - PT-101:
Phase 1 Study of Intravaginal Tamoxifen (PT-101): Randomized, double blind study of safety, pharmacokinetic (PK) and pharmacodynamics (PD) in menopausal patients with moderate to severe Vulvar and vaginal atrophy.
Fighting cervical cancer, FOGSI cervical cancer registry, a reaching the unreached FOGSI initiative 2010.
A pap smear & HIV DNA & colposcopy based study.
Study No. - DOCET_R_02271:
This is a multi-country, multi-centre, single arm non-interventional, prospective registry study.
Active implementation of Quality of Life (QOL) assessment in clinical practice for patients with advanced NSCLC and comparison of QOL and response endpoints.
Study No. - P1446A:
An open lable, Multicentre Phase 1 study of Selective Cyclin Dependent Kinase Inhibitor. In subjects with Advanced Refractory Malignancies.
Study No. - BIBF-1193.13:
A multicentre, randomized, double blind, Phase 3 Trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy in patients with stage IIIB/IV orrecurrent non small cell lung cancer after failure of first line chemotherapy.
|
|
|
|